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Abstract 21 
CRISPR technology has made genome editing widely accessible in model organisms and cells. 22 
However, conditional gene inactivation in diploid cells is still difficult to achieve. Here, we present 23 
CRISPR-FLIP, a strategy that provides an efficient, rapid, and scalable method for bi-allelic conditional 24 
gene knockouts in diploid or aneuploid cells such as pluripotent stem cells, 3D organoids and cell lines 25 
by co-delivery of CRISPR/Cas9 and a universal conditional intronic cassette. 26 
 27 
Introduction 28 
Analysing gene function is a crucial step in our understanding of normal physiology and disease 29 
pathogenesis.  In cell-based models, loss-of-function studies require inactivation of both copies of the 30 
gene.  Gene knockouts in cell lines were achieved by loss-of-heterozygosity1 or serial gene targeting 31 
approaches2.  The development of site-specific nucleases has greatly facilitated functional studies in 32 
cells due to the fact that both copies of a gene can be efficiently inactivated in a single step3.  Recently, 33 
the CRISPR/Cas9 gene editing technology4–7 has become the tool of choice for gene knockout studies 34 
due to its simplicity and robustness.  Cas9 nuclease is an RNA-guided nuclease that is highly efficient 35 
in inducing a double-strand break (DSB) at a genomic site of interest.  These DSBs can be repaired by 36 
error-prone non-homologous end joining (NHEJ) to generate gene-inactivating mutations or, in the 37 
presence of a donor template, the DSBs can be repaired by homology-directed repair (HDR) to 38 
generate more precise and complex alleles8.  While simple constitutive knockouts are useful and 39 
informative, it is desirable to engineer conditional loss-of-function models, particularly for genes 40 
essential for cell viability or embryonic development.  Here, we describe a simplified, one-step method 41 
for engineering conditional loss-of-function mutations in diploid cells.    42 
Existing methods for engineering conditional mutations in cultured cells9–12 rely on the inclusion of a 43 
drug selection cassette that must be removed in a second step to ensure proper expression of the 44 
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targeted conditional allele (Supplementary Fig 1a,b).  These methods were not designed for the 45 
generation of conditional loss-of-function models in a single step, particularly where the target gene 46 
is essential for cell growth or viability.  To overcome these limitations, our strategy combines an 47 
invertible intronic cassette (FLIP), similar to COIN12, with high efficiency Cas9-assisted gene editing. 48 
Critically, the non-mutagenic orientation of the FLIP cassette expresses a puromycin resistance gene 49 
(puroR) allowing selection of correct nuclease-assisted targeting into the exon of one allele and 50 
simultaneous enrichment of cells that inactivate the second allele by nuclease-mediated NHEJ (Fig 1a). 51 
Upon exposure to Cre recombinase the FLIP cassette is inverted to a mutagenic configuration that 52 
activates a cryptic splice acceptor and polyadenylation signal (pA) and disrupts the initial splicing 53 
acceptor resulting in the complete loss of gene function (Fig. 1b and Supplementary Fig. 2a). In 54 
contrast to COIN which requires the removal of the drug selection cassette, our FLIP cassette permits 55 
the generation of conditional mutant cells in one step.   56 
Initially we inserted a FLIP cassette variant containing a dsRed2 reporter in place of puroR into a CMV-57 
eGFP (enhanced green fluorescent protein) expression plasmid (CMV-eGFP[FLIP], Fig. 1c).  Following 58 
transient transfection of HEK293 cells with CMV-eGFP[FLIP], both green and red fluorescence was 59 
observed, demonstrating that insertion of the FLIP cassette in the non-mutagenic orientation is inert 60 
(Fig. 1d).  This was further confirmed by flow cytometry analysis showing similar level of eGFP 61 
expression from both CMV-eGFP and CMF-eGFP[FLIP] (Supplementary Fig. 3).   The Cre recombined 62 
CMV-eGFP[FLIP] showed loss of eGFP expression, suggesting the inactivation of eGFP expression in 63 
the inverted, mutagenic orientation of FLIP cassette (Fig. 1c,d).   64 
Next, we employed CRISPR/Cas9 endonuclease in mouse embryonic stem cells (mESCs) to introduce 65 
the puroR FLIP cassette into one allele of β-catenin (Ctnnb1) via HDR and to simultaneously induce a 66 
frameshift mutation by NHEJ in the second β-catenin allele (Fig. 1a, Supplementary Fig. 4a). β-catenin 67 
is an important gene for the morphology and efficient self-renewal of mESCs13,14. A donor vector 68 
containing the puroR FLIP cassette flanked by ~1 kb homology arms was inserted in exon 5 of β-catenin 69 
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by co-transfection of mESCs with Cas9 and gRNA expression plasmids. Following selection in 70 
puromycin, drug-resistant colonies were genotyped by PCR to confirm correct integration of the FLIP 71 
cassette and then assayed for NHEJ events in the second allele by Sanger sequencing (Supplementary 72 
Fig. 2b, 4b, c).  From 64 clones, 14 clones (21.9%) were correctly targeted, among which 4 clones 73 
carried a frame-shift mutation in the second allele (Supplementary table 1). The recovery of β-catenin 74 
compound mutant clones (FLIP targeted/NHEJ frameshift; FLIP/-) with wildtype morphology strongly 75 
suggests that the insertion of the FLIP cassette does not disrupt the function of β-catenin in the non-76 
mutagenic orientation. Upon expression of Cre recombinase in Ctnnb1FLIP/- clones, we observed a loss 77 
of β-catenin expression in cells (Fig. 2a, Supplementary Fig. 4d).  Moreover, compared to control 78 
(Ctnnb1FLIP/+) cells treated with Cre recombinase, the Ctnnb1FLIP/- cells became scattered and lost their 79 
dome-like morphology (Fig 2b). In addition, we performed quantitative RT-PCR analysis to determine 80 
the splicing efficiency of the FLIP intron in comparison to the neighbouring intron 7 of -catenin. Our 81 
data demonstrate highly efficient splicing of the FLIP intron. Thus the FLIP cassette is inert to gene 82 
activity in the non-mutagenic orientation (Supplementary Fig. 5 and Supplementary table 2).  83 
We additionally targeted Apc, Esrrb, Nfx1, Sox2, Tcf7l2, Trim13, and Trim37 in mESCs; ARID1A and 84 
TP53 in human HEK293 cells; and TP53 in human induced pluripotent stem cells (Supplementary Fig. 85 
6-9). The FLIP intron targeting efficiency ranged from 19.8% to 40.6% in mESCs (Supplementary table 86 
1, please note that non-targeted clones are a result of random integration of the puro cassette). 87 
Importantly, for all genes, FLIP/- clones were obtained (Supplementary table 1, Supplementary Fig. 88 
6-9). To induce gene knockout, a Cre expressing plasmid was transfected to ES clones with an average 89 
transfection efficiency higher than 95% (Supplementary Fig. 10) and  conditional inactivation of gene 90 
expression was confirmed by Western blot and immunofluorescence for Esrrb, Sox2, Trim13, and 91 
Trim37 (Supplementary Fig. 6d,6h,6i, 7m,7q).   92 
We further modified our FLIP intronic cassette to generate a reversible conditional allele.  The region 93 
containing the cryptic splice acceptor and pA is flanked by two FRT sites (Supplementary Fig. 11a, 94 
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FLIP-Flp Excision (FLIP-FlpE)).  When inserted into eGFP, the intronic FLIP-FlpE cassette permits the 95 
expression of eGFP like the original FLIP cassette (Supplementary Fig. 3, 11b).  Upon Cre 96 
recombination the FLIP-FlpE cassette turns into the mutagenic orientation, which blocks the eGFP 97 
expression.  Next, the added FRT sites enables the mutagenic FLIP-FlpE cassette to be excised by Flp 98 
recombinase, thus allowing the revival of eGFP expression (Supplementary Fig. 11a,b).  The FLIP-FlpE 99 
cassette was inserted in the 5th exon of the mouse -catenin allele.  The Ctnnb1FLIP-FlpE/ FLIP-FlpE (FLIP-FlpE 100 
homozygote) mutant clone went through a series of recombination, first by Cre and then Flp.  At each 101 
step, the mutant showed wildtype, mutant (after Cre), and again wildtype (after Cre and Flp) 102 
morphology, respectively (Supplementary Fig. 11e).  Accordingly, we observed loss and gain of β-103 
catenin expression (Supplementary Fig. 11f, g), suggesting that with a simple modification the FLIP 104 
intronic cassette can also be used for ‘switchable’ gene expression.  105 
To extend our application, we inserted the FLIP-FlpE cassette into the 16th exon of the mouse Apc 106 
allele in intestinal organoids expressing CreERT2 under the Villin promoter (Supplementary Fig. 12a). 107 
Apc is a component of the destruction complex acting in the Wnt pathway and its deletion causes 108 
hyperactive Wnt signalling and makes organoids adopt a cystic morphology15.  ApcFLIP-FlpE/- clones 109 
(Supplementary Fig 12b, c) initially showed budding morphology when cultured in standard ENR (Egf, 110 
Noggin, Rspondin) media. Upon treatment with 4-hydroxytamoxifen (4-OHT), for Cre activation, the 111 
organoids adopt a cystic morphology due to the loss of Apc (Supplementary Fig. 12d). In addition to 112 
the application of CRISPR-FLIP to intestinal organoids, FLIP-targeted ES clones can be used to generate 113 
other cell types e.g. mouse embryonic fibroblast (MEF) (Supplementary Fig. 13).  114 
Discussion 115 
Our strategy requires the presence of a CRISPR site overlapping or nearby the insertion site of the FLIP 116 
cassette, imposing constraints on the exons than can be targeted.  To maximize the potential for a null 117 
mutation, the target exon must be common to all transcripts and lie within the first 50% of the protein-118 
coding sequence.  Additionally, based on the minimum size of mammalian exons (50 bp)16, we set the 119 
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size of the split exons to be at least 60 bp.  Finally, for optimal splicing, we chose insertion points that 120 
match the consensus sequence for mammalian splice junctions (minimally MAGR (A/CAG/Pu))17. Using 121 
this set of rules, we used bioinformatics to estimate the number of suitable FLIP insertion sites in the 122 
protein-coding genes in the mouse and human genomes. Our bioinformatics analysis revealed 123 
1,171,712 FLIP insertion sites and corresponding gRNA binding sites covering 16,460 genes in the 124 
mouse genome and 1,171,787 FLIP insertion sites and corresponding gRNA binding sties covering 125 
15,177 genes in the human genome. (Supplementary table 3,4). Although haploinsufficient genes 126 
impose a limitation to our strategy, as one allele is already null in FLIP/- clones, the generation of 127 
FLIP/FLIP clones provide an option for haploinsufficient genes. 128 
Recently developed methods used to achieve higher HDR-mediated targeting efficiency are likely to 129 
further increase the efficiency of our CRISPR-FLIP method18. The FLIP targeting vectors only require 130 
short homologous arms (less than 1 kb) which makes the assembly of targeting vectors easy and 131 
scalable.  The FLIP cassette is invariable and can be generically applied to any gene, including non-132 
coding RNA genes.  The CRISPR-FLIP technology is widely applicable to many diploid and aneuploid 133 
cell types including mESCs, fibroblasts, 3D organoids, hiPSCs, and cell lines (e.g. 293 cells).   134 
Data availability 135 
Mammalian expression plasmids are available at Addgene. pUC118-FLIP-Puro (#84538 for generation 136 
of conditional knockouts), pUC118-FLIP-FlpE-Puro (#84539 for generation of reversible conditional 137 
knockouts), pUC118-mCtnnb1-FLIP-Puro (#84540, FLIP vector for conditional knockout of Ctnnb1), 138 
pUC118-mCtnnb1-FLIP-FlpE-Puro (#84541, FLIP-FlpE vector for reversible conditional knockout of 139 
Ctnnb1) and gRNA-mCtnnb1 (#84542). 140 
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Figure Legends 206 
Figure 1. FLIP cassette strategy for bi-allelic conditional gene modification 207 
(a) Schematic drawing of the FLIP cassette strategy for bi-allelic conditional gene modification. [Since 208 
the process is described in the Figure it does not need to be explained again in the legend.  209 
(b) The design of the FLIP cassette.  210 
SD – splice donor, SA1, SA2 – splice acceptor, Purple triangles - LoxP1 sites Pink triangles – Lox5171 211 
sites BP1, BP2 (blue circles) – branching point, pA - polyadenylation signal.  212 
(c) Schematic of the FLIP cassette containing a DsRed reporter gene  213 
(d)  Images of HEK 293 cells transfected with the FLIP cassette. Both eGFP and DsRed proteins are 214 
expressed (top row ). After Cre recombination the eGFP expression is disrupted, and only DsRed 215 
expression is maintained (bottom row). Scale bar 400 µm. 216 
 217 
Figure 2. Insertion of the FLIP cassette in the endogenous Ctnnb1 gene of mouse embryonic stem 218 
cells.  219 
(a) Immunofluorescence of -catenin before and after Cre transfection.  220 
(b) Representative bright field images of the ESC clones before (top) and after (bottom) Cre 221 
transfection. Scale bar 400μm.   222 
 223 
  224 
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Online methods 225 
dsRed FLIP cassette inserted in the eGFP cDNA 226 
The FLIP cassette inserted in the middle of eGFP and containing a dsRed2 reporter gene was 227 
synthesized and ordered from GenScript.  The split eGFP cDNA and the FLIP cassette were cloned into 228 
the mammalian expression vector pCDNA4TO (Invitrogen) using BamHI (R0136S, NEB) and XhoI 229 
(R0146S, NEB) for pre-recombined form. The vector was subsequently transformed into Cre 230 
expressing bacteria (A111, Gene bridges) to generate the Cre-recombined form. Correct clones were 231 
confirmed with restriction digest BamHI (R0136S, NEB) and XhoI (R0146S, NEB) and Sanger 232 
sequencing. The FLIP-FlpE cassette was also synthesized and inserted into the same site of the eGFP 233 
expression vector.  234 
FLIP cassette containing selection marker genes 235 
The FLIP cassette was PCR amplified and cloned into Pjet1.2 vector (ThermoFisher Scientific, K131). 236 
Replacement of dsRed was done through restriction digest excision using EcoRI (R3101S, NEB) and 237 
Acc65l (RO599S, NEB) followed by insertion of PCR amplified selection marker genes using Infusion 238 
cloning (638909, Clontech). The FLIP cassette including selection marker gene was then transferred to 239 
the vector pUC118 (3318, Clontech) using the restriction enzymes SacI (R0156S, NEB) and PstI 240 
(R0140S, NEB) and Mighty cloning (6027, Takara).  241 
Addition of homologous arms to the FLIP cassette – FLIP targeting vector generation 242 
Homologous arms around an intron insertion site were amplified by high fidelity Phusion DNA 243 
polymerase (M0530S, NEB). After PCR product purification, both homologous arms and FLIP cassette-244 
containing vector were mixed with the type II restriction enzyme SapI and T4 DNA ligase (M0202T, 245 
NEB). After 25 cycles of 37°C and 16°C, the reaction mixture was directly used for E.Coli 246 
transformation. DNA was extracted (27106, Qiagen) and analysed with restriction digest to identify 247 
correctly assembled FLIP donor vectors.  248 
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Cas9 and gRNA plasmids 249 
Human codon optimized Cas9 (41815, Addgene) and empty gRNA vector (41824, Addgene) were 250 
obtained from Addgene.  251 
Cell culture  252 
Human embryonic kidney (HEK) 293 cells 253 
Human embryonic kidney 293 cells were cultured in media consisting of DMEM, high glucose 254 
(11965092, Thermofisher Scientific) supplemented with 10% foetal bovine serum (Thermofisher 255 
Scientific), 1x penicillin-streptomycin according to the manufacturer’s recommendation (P0781, 256 
Sigma). The cells were tested negative for mycoplasma. 257 
Embryonic stem cells (ESCs) 258 
Murine E14 Tg2a embryonic stem (mES) cells were cultured feeder-free on 0.1% gelatin-coated dishes 259 
in serum+LIF+2i (Chiron and PD03) composed of GMEM (G5154, Sigma), 10% foetal bovine serum 260 
(Gibco), 1x non-essential amino acids according to the manufacturer’s recommendation (11140, 261 
Thermofisher Scientific), 1 mM sodium pyruvate (113-24-6, Sigma),  2 mM L-glutamine (25030081, 262 
Thermofisher Scientific), 1x penicillin-streptomycin according to the manufacturer’s recommendation 263 
(P0781, Sigma) and 0.1 mM 2-mercaptoethanol (M7522, Sigma), 20 ng/ml murine LIF (Hyvonen lab, 264 
Cambridge), 3 μM CHIR99021 and 1 μM PD0325901 (Stewart lab, Dresden).  BOBSC19 human induced 265 
pluripotent stem (hiPS) cells were cultured feeder-free on dishes coated with Synthemax II (3535, 266 
Corning) in TeSR-E8 media (05940, Stem Cell Technologies). ESCs were kept in a tissue culture 267 
incubator at 37°C and 5% CO2.  Cells were split in a 1:10 – 1:15 ratio every 3-4 days depending on 268 
confluence. All cells were tested negative for mycoplasma. 269 
Intestinal organoid culture 270 
Mouse small intestinal organoids were cultured as previously described20. 271 
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Cell electroporation 272 
For targeting of mESCs 1x106 cells were collected and resuspended in magnesium and calcium free 273 
phosphate buffered saline (D8537, Sigma). A total of 50 µg of DNA consisting of the targeting vector, 274 
Cas9 and gRNA in a 1:1:1 ratio were added to the cells and then transferred to a 4 mm electroporation 275 
cuvette (Biorad). Electroporation was performed using the Biorad Gene Pulser XCell’s (165-2660, 276 
Biorad) exponential program and the following settings: 240 V, 500 uF, unlimited resistance.  For 277 
targeting of human iPS cells, 2x106 cells were dissociated with Accutase (SCR005, Millipore) and 278 
resuspended in nucleofection buffer (Solution 2, LONZA).  A total of 12 µg of DNA consisting of 4 µg 279 
Cas9 plasmid, 4 µg of each gRNA plasmid and 4 µg of targeting vector was added to the cells and 280 
transferred to a 100 µl nucleofection cuvette (LONZA).  Nuclefection was performed with the AMAXA 281 
Human Nucleofector Kit 2 (LONZA Cat # VPH-5022) using the B-016 program.   The cells were plated 282 
and cultured for 1 day in TeSR-E8 media (05940, STEM CELL technologies) containing ROCK inhibitor 283 
(Y-27632, Stem Cell Technologies) to promote survival of transfected cells. For targeting of HEK293 284 
cells, the cells were cultured until they reached 50-60% confluence. A total of 8 µg of DNA consisting 285 
of targeting vector, Cas9 and gRNA in a 1:1:1 ratio was transfected using Lipofectamine-2000 286 
(11668019, Invitrogen) according to the manufacturer’s instructions.  287 
Plasmid transfection 288 
1 µg of pCAGGS-Cre-IRES-Puro and/or pCAGGS-Flp-IRES-Puro plasmid vector and 3 µl of 289 
Lipofectamine-2000 (11668019, Invitrogen) were mixed according to the manufacturer’s protocol, 290 
applied to 2x106 recently seeded (less than 30 min) cells/ 6-well and incubated overnight. Media was 291 
refreshed the following morning. Ctnnb1FLIP/+ and Ctnnb1FLIP/- with CreERT2 clones were generated by 292 
transfecting 0.66 μg of PiggyBac CreERT2 expressing plasmid (with hygromycin 50 μg/ml) together 293 
with 0.33 μg of transposase using Lipofectamine-2000 as described above. Cre-recombinase was 294 
activated by adding 4-OHT with a final concentration of 1 μM for 48h.  295 
Western blot 296 
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Following transfection ESCs were cultured for 2-5 days and then lysed in buffer containing complete 297 
protease-inhibitor cocktail tablets (11697498001, Roche) and centrifuged at 13,000 rpm for 15 min at 298 
4°C. Protein concentration was measured with Bradford assay (5000204, Biorad) and equal amounts 299 
were loaded on a 10% acrylamide gel and run at 120 V for 1.5-2hrs.  The proteins were subsequently 300 
transferred to an Immobilon-FL PVDF 0.45 µm membrane (IPFL00010, Millipore) at 90 V for 1hr 15 301 
min. The following primary antibodies and dilutions were used to detect the indicated proteins: Rabbit 302 
monoclonal antibody against β-Catenin (1:1000, 8480S, Cell Signaling), mouse monoclonal against 303 
alpha Tubulin antibody (1:5000, ab7291, Abcam), mouse monoclonal antibody against beta-actin 304 
(1:5000, ab8226, Abcam), mouse monoclonal antibody against Esrrb, (1:1000, PP-H6705-00, Bio-305 
Techne), rat monoclonal antibody against Sox2, (1:500, 14-9811-80, eBioscience), mouse monoclonal 306 
antibody against Trim 13 (1:500, sc-398129, Santa Cruz), mouse monoclonal antibody against Trim37 307 
(1:500, sc-514828, Santa Cruz) and rabbit monoclonal against Vinculin (1:3000, ab19002, Abcam). The 308 
membrane was washed and the indicated horseradish-peroxidase conjugated secondary antibodies 309 
were applied: horse anti-mouse IgG (1:5000, Cell Signaling) and goat anti-rabbit (1:5000, Cell Signaling) 310 
and goat anti-rat HRP conjugated (1:5000, SC2032, Santa Cruz). Detection was achieved using ECL 311 
prime Western blotting Detection system (RPN2133, GE Healthcare). 312 
Immunofluorescence 313 
Cells were cultured in Ibid tissue culture dishes (IB-81156, Ibid) coated with 0.1% gelatin, washed twice 314 
with calcium and magnesium free PBS and fixed in 4% PFA for 20 min at RT. The cells were 315 
permeabilised in 0.5% Triton X-100 (T8787, Sigma) in PBS for 15 min at RT. Subsequently, blocking was 316 
performed in 5% donkey serum (D9663, Sigma) and 0.1% Triton X-100 for 1hr at RT. The following 317 
primary antibodies in blocking buffer were applied for the indicated protein: Sox2, (1:500, 14-9811-318 
80, eBioscience) and β-Catenin (1:1000, 4627, Cell Signaling). Primary antibodies were incubated 319 
overnight at 4°C. Subsequently excess primary antibody was washed away and anti-rat Alexa Flour 320 
594® conjugated antibody (1:1000, A21209, Abcam) was added for Sox2, and incubated for 1h at RT. 321 
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Excess secondary antibody was washed away and DAPI (1:1000, D9542, Sigma) was added and 322 
incubated for 10 min at RT. Cells were washed and mounted in RapiClear (RCCS002, Sunjin lab). 323 
Chimeric embryo generation and ESC-derived fibroblast establishment 324 
Sox2FLIP/FLIP mESCs transfected with pPyCAG-eGFP-IRES-Zeo plasmid were aggregated. Chimerae were 325 
generated by standard aggregation using F1 embryos and transplanted into pseudopregnant recipient 326 
mice of C57BL/6J strain.  E13.5 embryos were beheaded and dissected to remove all organs, including 327 
genital ridges.  The remaining body was cut into small pieces, trypsinised, and plated on gelatin in 328 
serum+LIF media containing selecting reagents. GFP expression confirms that the MEFs are derived 329 
from the Sox2FLIP/FLIP mESCs. All animal work was performed in accordance with Home Office guidelines 330 
and regulations at the University of Cambridge, UK. 331 
Quantitative RT-PCR 332 
Total RNA was extracted using RNwasy Mini kit (74104, Qiagen) with an on-column DNase digestion 333 
(79254, Oiagen). Reverse transcription was performed using 250 ng of RNA using M-MLV Reverse 334 
Transcriptase (M1701, Promega).  Quantitative PCR reactions were performed in triplicates using iQ 335 
SYBR Green Supermix according to the manufacturer’s protocol (1708882, Biorad) with the primers in 336 
Supplementary table 2 and the StepOnePlus Real Time PCR System (Applied Biosystems). Average 337 
gene expression was normalized to exon5 and error bars represent ± standard deviation. 338 
Flow cytometry analysis  339 
HEK 293 cells were co-transfected with eGFP, eGFP[FLIP] or eGFP[FLIPFlpE] and a BFP reporter as 340 
described previously, and harvested 24h post transfection. mESCs were transfected with eGFP as 341 
describes above and harvested 48h post transfection. Cells were analysed using BD LSRFortessa (BD 342 
Biosciences) and Flowjo software. 343 
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